Longboard Pharmaceuticals, Inc. (LBPH)

4.1500 -0.1900 (-4.38%) At close: 04:00PM EDT

Longboard Pharmaceuticals, Inc.

4275 Executive Square
Suite 950
La Jolla, CA 92037
United States
619 592 9775
https://www.longboardpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 21

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Kevin R. Lind	Pres, CEO, Sec. & Director	875.13k	N/A	1976
Ms. Brandi L. Roberts CPA, M.B.A.	Chief Financial Officer	568.57k	N/A	1974
Mr. Chadwick J. Orevillo MPH	VP & Head of Operations	N/A	N/A	N/A
Megan E. Knight	Head of Investor Relations	N/A	N/A	N/A
Mr. Steven W. Spector J.D.	Head of Bus. Devel. & Gen. Counsel	N/A	N/A	1965
Dr. Anne M. Danks	VP & Head of Preclinical Devel.	N/A	N/A	N/A
Dr. Jodi Parsons	VP & Head of Regulatory Affairs	N/A	N/A	N/A
Dr. Randall E. Kaye M.D.	Chief Medical Officer	N/A	N/A	1962
Mr. Gus Cardenas	VP & Head of Quality Assurance	N/A	N/A	N/A
Dr. Marco Peters Ph.D.	VP & Head of Translational Science	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Corporate Governance

Longboard Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.